跳至主要内容
临床试验/CTRI/2025/03/083118
CTRI/2025/03/083118尚未招募4 期

Comparison of sugammadex and sugammadex combined with neostigmine for reversal of vecuronium induced neuromuscular blockade in patients undergoing general anaesthesia : A randomised clinical trial

Anellia Dari I Ka Massar1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2025年4月30日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
120
试验地点
1
主要终点
The time (in minutes) taken from the start of administration of the study drug (sugammadex or sugammadex combined with neostigmine) to the appearance of second twitch of train of four stimulation till recovery of normalised TOF ratio of 0.9 or more.

研究概览

简要总结

The use of neuromuscular blocking agents during induction of anaesthesia, facilitates intubation and improve surgical access by providing muscle relaxation and maintaining deep neuromuscular blockade until the end of the operation. Rapid reversal of neuromuscular blockade at the end of surgery is desirable to enhance patient safety and to avoid post operative complications like residual neuromuscular blockade.

Sugammadex is a novel agent without cholinergic side effects that specifically binds to steroidal neuromuscular blocking agents like vecuronium and rocuronium, reversing their effects and thus, rapidly restoring neuromuscular function.  The use of sugammadex along with neostigmine can enhance neuromuscular recovery, thereby allowing for a lower dosage of sugammadex to be administered. By reducing the dosage of sugammadex, it can lower the overall cost of sugammadex while its efficacy is preserved.

Hence, in this study we want to compare sugammadex and sugammadex combined with neostigmine for reversal of vecuronium induced neuromuscular blockade in patients undergoing general anaesthesia. After obtaining ethical clearance and written informed consent, a total number of 120 patients between 18-60 years of ASA physical status I and II undergoing elective surgery under general anaesthesia in the Department of Anaesthesiology, Regional Institute of Medical Sciences, Imphal, Manipur will be randomly divided into two groups of 60 each. Group A patients will receive sugammadex at a dose of 2 mg/kg and Group B patients will receive a combination of sugammadex 1 mg/kg with neostigmine 50 mcg/kg and glycopyrrolate 10 mcg/kg for reversal of vecuronium induced neuromuscular blockade when two twitches to train of four stimulation appear. After administration of reversal agent, the time taken from the start of administration of the study drugs to the appearance of second twitch of train of four stimulation till recovery of its normalised ratio of 0.9 will be compared between the two groups. Additionally, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), oxygen saturation (SpO2) and heart rate (HR) will be recorded. All the findings and observations made during the entire study will be recorded in a proforma, tabulated in the EXCEL software and statistically analysed using SPSS software. Inference will be drawn to evaluate and compare the study drugs along with their clinical advantages and adverse effects.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients aged 18 to 60 years of either gender – male or female.
  • Patients with American Society of Anaesthesiologists (ASA) physical status Grade I to Grade II.

排除标准

  • Patient’s refusal.
  • Patients with suspected difficult airway.
  • Patients with body mass index (BMI) more than 30 kg/m
  • Patients with known allergy to sugammadex, neostigmine and vecuronium.
  • Patients with pre-existent clinical conditions like chronic obstructive pulmonary disease, severe renal dysfunction, hepatic disease, cardiovascular disease, neurodegenerative disease and neuromuscular disease.
  • Pregnant or breastfeeding patients.

结局指标

主要结局

The time (in minutes) taken from the start of administration of the study drug (sugammadex or sugammadex combined with neostigmine) to the appearance of second twitch of train of four stimulation till recovery of normalised TOF ratio of 0.9 or more.

时间窗: Outcome will be measured in a single time point, i.e. from the point of administration of study drug (baseline),till attainment of train of four ratio of 0.9 .

次要结局

  • Hemodynamic parameters like Blood pressure, pulse rate, spo2, heart rate & also any adverse effects like bradycardia, tachycardia, hypotension, anaphylaxis, nausea(or vomiting.)

研究者

发起方
Anellia Dari I Ka Massar
申办方类型
Other [Post Graduate Trainee]
责任方
Principal Investigator
主要研究者

ANELLIA DARI I KA MASSAR

Regional Institute of Medical Sciences, Imphal, Manipur

研究点 (1)

Loading locations...

相似试验